{"brief_title": "CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma", "brief_summary": "The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.", "condition": ["Multiple Myeloma"], "intervention_type": ["Drug"], "intervention_name": ["CDC-501"], "criteria": "- Subject must be diagnosed with multiple myeloma (with measurable M-Protein in serum and/or urine), and be considered to have disease progression after at least two cycles of treatment or have relapsed after treatment. - Subject must understand and voluntarily sign an informed consent document. - Subject must not have received corticosteroids, other chemotherapy, thalidomide, or other investigational agents, within 21 days of baseline - ECOG (Zubrod) performance status of 0 to 2. - Subject must be able to adhere to the study visit schedule and other protocol requirements. - Women of childbearing potential (WCBP ) must have a negative serum or urine pregnancy test within 7 days of baseline. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study drug.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "CC5013", "mesh_term": ["Multiple Myeloma", "Neoplasms, Plasma Cell", "Lenalidomide"], "id": "NCT00044018"}